Iterum Therapeutics plc
ITRM · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $254 | $1,750 | $1,800 | $2,104 |
| Gross Profit | -$254 | -$1,750 | -$1,800 | -$2,104 |
| % Margin | – | – | – | – |
| R&D Expenses | $10,458 | $38,242 | $15,817 | $8,608 |
| G&A Expenses | $7,984 | $0 | $0 | $0 |
| SG&A Expenses | $7,984 | $7,476 | $12,766 | $13,825 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $18,442 | $45,718 | $28,583 | $22,433 |
| Operating Income | -$18,696 | -$47,468 | -$30,383 | -$24,537 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$5,838 | $9,710 | -$13,750 | -$66,322 |
| Pre-Tax Income | -$24,534 | -$37,758 | -$44,133 | -$90,859 |
| Tax Expense | $240 | $613 | $301 | $705 |
| Net Income | -$24,774 | -$38,371 | -$44,434 | -$91,564 |
| % Margin | – | – | – | – |
| EPS | -1.26 | -2.96 | -3.63 | -8.41 |
| % Growth | 57.4% | 18.5% | 56.8% | – |
| EPS Diluted | -1.26 | -2.96 | -3.63 | -8.41 |
| Weighted Avg Shares Out | 19,699 | 12,962 | 12,237 | 10,891 |
| Weighted Avg Shares Out Dil | 19,699 | 12,962 | 12,237 | 10,891 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $1,428 | $2 | $5 |
| Interest Expense | $0 | $0 | $2,361 | $5,553 |
| Depreciation & Amortization | $284 | $1,750 | $1,800 | $2,104 |
| EBITDA | -$21,728 | -$34,580 | -$39,972 | -$83,202 |
| % Margin | – | – | – | – |